Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11475560 | 0.84 | CYP3A4 (0.55) | CYP3A4TDP1MAPK1TRPA1ALDH1A1 | |
| SCHEMBL10316759 | 0.82 | CYP3A4 (0.48) | CYP3A4TDP1MAPK1TRPA1ALDH1A1 | |
| SCHEMBL1969003 | 0.81 | TDP1 (0.47) | CYP3A4TDP1MAPK1TRPA1ALDH1A1 | |
| SCHEMBL11849090 | 0.80 | CYP3A4 (0.46) | CYP3A4TDP1MAPK1TRPA1ALDH1A1 | |
| SCHEMBL9063336 | 0.78 | CYP3A4 (0.53) | CYP3A4TDP1MAPK1TRPA1ALDH1A1 | |
| SCHEMBL17196712 | 0.78 | CYP3A4 (0.44) | CYP3A4TDP1TRPA1ALDH1A1HPGD | |
| SCHEMBL9551404 | 0.78 | CYP3A4 (0.50) | CYP3A4TDP1MAPK1TRPA1ALDH1A1 | |
| SCHEMBL1493105 | 0.78 | TDP1 (0.44) | CYP3A4TDP1MAPK1TRPA1ALDH1A1 | |
| SCHEMBL29796026 | 0.78 | CYP3A4 (0.50) | CYP3A4TDP1MAPK1TRPA1ALDH1A1 | |
| SCHEMBL28565927 | 0.77 | CYP3A4 (0.52) | CYP3A4TDP1MAPK1TRPA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-5270302-A | Derivatives of tetrapeptides as CCK agonists | ABBOTT LABORATORIES (US) | 1993-12-14 | — | — | US | disclosed |
| WO-1991019733-A1 | DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS | ABBOTT LABORATORIES (US) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | CYP3A4 916/4885TDP1 2982/4885MAPK1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.